Generation Bio (NASDAQ:GBIO) shares are trading higher on Thursday after the company and Moderna (NASDAQ:MRNA) announced a collaboration to develop non-viral genetic medicines. The company will receive a $40 million upfront cash payment and a $36 million equity investment from Moderna.
The collaboration aims to expand the application of each company’s platform by developing novel nucleic acid therapeutics to accelerate their pipelines of non-viral genetic medicines.
As part of the agreement, Moderna has acquired an option to license Generation Bio’s ctLNP and ceDNA for two liver programs and two immune cell programs. as well as am option for a third program.
“This collaboration represents a foundational investment in our platform science, both deepening our pipeline of rare and prevalent liver disease programs beyond hemophilia A and accelerating our work to reach outside of the liver with nucleic acid therapies,” said Phillip Samayoa, Ph.D., Chief Strategy Officer of Generation Bio.
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases.
GBIO Price Action: Generation Bio has a 52-week high of $9.59 and a 52-week low of $3.40.
Generation Bio shares are up 32.7% at $5.15 at the time of writing, according to Benzinga Pro.
